Ms. Holly M. Marcum

• 
  incyte.com/about_press_releases_20010411.html - [Cached Version]
  Published on: 4/11/2001    Last Visited: 3/3/2007  

  For additional information on licensing these patents, interested parties should contact Holly Marcum, Sr. Director of Corporate Development, at 650.621.7608.

• 
  www.newsrx.net/scripts/issues_partial.cgi/?issuedate=20 - [Cached Version]
  Published on: 6/19/2002    Last Visited: 2/26/2003  

  Cesar R. Collado joins as vice president of business development and commercialization and Holly M. Marcum joins as executive director of business development and commercialization. ... (viewing 352 of 2936 characters)

• 
  "The free stock market game which gives away prizes... - [Cached Version]
  Published on: 7/15/2001    Last Visited: 7/15/2001  

  For additional information on licensing these patents , interested partiesshould contact Holly Marcum , Sr. Director of Corporate Development , at650-621-7608
  
  Incyte Genomics , Inc. is the leading provider of an integrated platform ofgenomic technologies designed to aid in the understanding of the molecularbasis of disease.Incyte develops and markets genomic databases andpartnership programs , genomic data management software , microarray based geneexpression services , related reagents and services.These products , programs , and services assist pharmaceutical and biotechnology researchers with allphases of drug discovery and development , including gene discovery , understanding disease pathways , identifying new disease targets and thediscovery and correlation of gene sequence variation to disease.For moreinformation , visit Incyte's web site at www.incyte.com.
  
  Merck & Co. , Inc. is a leading research-driven pharmaceutical products andservices company.

• 
  Amphora Discovery Corp : Press Releases - [Cached Version]
  Published on: 1/7/2002    Last Visited: 10/1/2002  

  Cesar R. Collado joins as Vice President of Business Development and Commercialization and Holly M. Marcum joins as Executive Director of Business Development and Commercialization.
  ...
  Mr. Collado and Ms. Marcum each have significant business development experience in the pharmaceutical and biotechnology industries and will be responsible for commercial development activities at Amphora Discovery.
  ...
  "We are excited to have Cesar and Holly leading our business development and commercialization efforts at Amphora.
  ...
  Cesar brings significant breadth and experience doing strategic transactions for Eli Lilly & Co., and Holly has extensive business development experience in biotechnology and life sciences.
  ...
  "Cesar and Holly bring complementary experiences and skill sets which will enable Amphora to fully leverage our technologies for strategic value creation."
  ...
  Ms. Marcum has over ten years of experience in the biotechnology and life science industries in positions of increased responsibility in corporate business development and sales and marketing.Most recently, Ms. Marcum was Senior Director of Corporate Development for Incyte Genomics, where she negotiated, structured and implemented numerous strategic partnerships with companies utilizing Incyte's gene information and intellectual property for commercial purposes.Prior to Incyte, Ms. Marcum held various key positions in business development and sales and marketing at Perkin Elmer Life Sciences Corporation and Life Technologies, Inc.Ms. Marcum received her B.A. in Molecular Biology from Middlebury College and is currently completing her MBA at Duke University's Fuqua School of Business.
  
  Amphora Discovery Corp. is a newly-formed drug discovery company whose aim is to improve the drug discovery and development process and generate high quality drug candidates across important classes of therapeutic targets.Amphora is leveraging its know-how and exclusive technology rights in microfluidics to generate and commercialize a knowledge base of chemical genomics information of unprecedented quality and scale.The chemical genomics knowledge base, which will detail the interactions of small molecules against a broad array of biological targets, will include data on potency, specificity, drug absorption, metabolism, toxicology and physical properties of individual molecules.The information will be instrumental in preclinical drug discovery, acceleration of target validation, lead identification and medicinal chemistry, as well as in increasing the success rate of drugs through clinical development.Utilization of information of this quality and breadth will revolutionize the drug discovery process, shortening the period from biology discovery to useful medicine and enabling the development of better drugs, faster and more economically.

• 
  BioExchange - Life Sciences and Biotechnology Resource... - [Cached Version]
  Published on: 4/11/2001    Last Visited: 6/16/2001  

  For additional information on licensing these patents , interested parties should contact Holly Marcum , Sr. Director of Corporate Development , at 650-621-7608.
  
  Incyte Genomics , Inc. is the leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease.Incyte develops and markets genomic databases and partnership programs , genomic data management software , microarray-based gene expression services , related reagents and services.These products , programs , and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development , including gene discovery , understanding disease pathways , identifying new disease targets and the discovery and correlation of gene sequence variation to disease.For more information , visit Incyte's web site at http : //www.incyte.com/.
  
  Merck & Co. , Inc. is a leading research-driven pharmaceutical products and services company.

• 
  MPM Capital - Portfolio Company News - [Cached Version]
  Published on: 6/17/2002    Last Visited: 5/15/2008  

  Cesar R. Collado joins as Vice President of Business Development and Commercialization and Holly M. Marcum joins as Executive Director of Business Development and Commercialization.
  ...
  Mr. Collado and Ms. Marcum each have significant business development experience in the pharmaceutical and biotechnology industries and will be responsible for commercial development activities at Amphora Discovery.
  ...
  "We are excited to have Cesar and Holly leading our business development and commercialization efforts at Amphora.
  ...
  Cesar brings significant breadth and experience doing strategic transactions for Eli Lilly & Co., and Holly has extensive business development experience in biotechnology and life sciences.
  ...
  "Cesar and Holly bring complementary experiences and skill sets which will enable Amphora to fully leverage our technologies for strategic value creation."
  ...
  Ms. Marcum has over ten years of experience in the biotechnology and life science industries in positions of increased responsibility in corporate business development and sales and marketing.Most recently, Ms. Marcum was Senior Director of Corporate Development for Incyte Genomics, where she negotiated, structured and implemented numerous strategic partnerships with companies utilizing Incyte's gene information and intellectual property for commercial purposes.Prior to Incyte, Ms. Marcum held various key positions in business development and sales and marketing at Perkin Elmer Life Sciences Corporation and Life Technologies, Inc.Ms. Marcum received her B.A. in Molecular Biology from Middlebury College and is currently completing her MBA at Duke University's Fuqua School of Business.

• 
  Merck Licenses Enabling Microarray Manufacturing and... - [Cached Version]
  Published on: 4/11/2001    Last Visited: 12/13/2001  

  For additional information on licensing these patents, interested parties should contact Holly Marcum, Sr. Director of Corporate Development, at 650.621.7608.
  
  Incyte Genomics, Inc. is the leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease.Incyte develops and markets genomic databases and partnership programs, genomic data management software, microarray-based gene expression services, related reagents and services.These products, programs, and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development, including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease.For more information, visit Incyte's web site at www.incyte.com.
  
  Merck & Co., Inc. is a leading research-driven pharmaceutical products and services company.

• 
  Merck Licenses Enabling Microarray Manufacturing and... - [Cached Version]
  Published on: 4/11/2001    Last Visited: 2/4/2003  

  For additional information on licensing these patents, interested parties should contact Holly Marcum, Sr. Director of Corporate Development, at 650.621.7608.
  
  Incyte Genomics, Inc. is the leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease.Incyte develops and markets genomic databases and partnership programs, genomic data management software, microarray-based gene expression services, related reagents and services.These products, programs, and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development, including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease.For more information, visit Incyte's web site at www.incyte.com.
  
  Merck & Co., Inc. is a leading research-driven pharmaceutical products and services company.

• 
  OnMoney Investing Advisor for Online Consumers - News - [Cached Version]
  Published on: 12/18/2000    Last Visited: 4/14/2001  

  For additional information on licensing these patents , interested parties should contact Holly Marcum , Sr. Director of Corporate Development , at 650-621- 7608.
  
  Incyte Genomics , Inc. is the leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease.Incyte develops and markets genomic databases and partnership programs , genomic data management software , microarray-based gene expression services , related reagents and services.These products , programs , and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development , including gene discovery , understanding disease pathways , identifying new disease targets and the discovery and correlation of gene sequence variation to disease.For more information , visit Incyte's web site at www.incyte.com.
  
  Merck & Co. , Inc. is a leading research-driven pharmaceutical products and services company.

• 
  Today's News - [Cached Version]
  Published on: 6/17/2002    Last Visited: 6/17/2002  

  Cesar R. Collado joins as Vice President of Business Development and Commercialization and Holly M. Marcum joins as Executive Director of Business Development and Commercialization.
  ...
  Mr. Collado and Ms. Marcum each have significant business development experience in the pharmaceutical and biotechnology industries and will be responsible for commercial development activities at Amphora Discovery.
  ...
  "We are excited to have Cesar and Holly leading our business development and commercialization efforts at Amphora.
  ...
  Cesar brings significant breadth and experience doing strategic transactions for Eli Lilly & Co., and Holly has extensive business development experience in biotechnology and life sciences.
  ...
  "Cesar and Holly bring complementary experiences and skill sets which will enable Amphora to fully leverage our technologies for strategic value creation."
  ...
  Ms. Marcum has over ten years of experience in the biotechnology and life science industries in positions of increased responsibility in corporate business development and sales and marketing.Most recently, Ms. Marcum was Senior Director of Corporate Development for Incyte Genomics, where she negotiated, structured and implemented numerous strategic partnerships with companies utilizing Incyte's gene information and intellectual property for commercial purposes.Prior to Incyte, Ms. Marcum held various key positions in business development and sales and marketing at Perkin Elmer Life Sciences Corporation and Life Technologies, Inc.Ms. Marcum received her B.A. in Molecular Biology from Middlebury College and is currently completing her MBA at Duke University's Fuqua School of Business.
  
  Amphora Discovery Corp. is a newly-formed drug discovery company whose aim is to improve the drug discovery and development process and generate high quality drug candidates across important classes of therapeutic targets.Amphora is leveraging its know-how and exclusive technology rights in microfluidics to generate and commercialize a knowledge base of chemical genomics information of unprecedented quality and scale.The chemical genomics knowledge base, which will detail the interactions of small molecules against a broad array of biological targets, will include data on potency, specificity, drug absorption, metabolism, toxicology and physical properties of individual molecules.The information will be instrumental in preclinical drug discovery, acceleration of target validation, lead identification and medicinal chemistry, as well as in increasing the success rate of drugs through clinical development.Utilization of information of this quality and breadth will revolutionize the drug discovery process, shortening the period from biology discovery to useful medicine and enabling the development of better drugs, faster and more economically.

Page:  1 2